Similarly, the difference between riluzole and placebo group did not reach statistical significance at the 0.05 level when assessed using Wilcoxon test with adjustment for multiple comparisons.
← all excerpts
The sodium-glutamate antagonist riluzole improves outcome after acute spinal cord injury: results from the RISCIS randomised controlled trial analysed using a global statistical analytic technique.
1
—
—